Search

Displaying results 4061 - 4070 of 9887 in total
  1. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. … 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de

  2. Drug

    Ecraprost

    go.drugbank.com/drugs/DB16148
    Investigational

    Ecraprost is under investigation in clinical trial NCT00059657 (Efficacy/safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease).

  3. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

  4. Drug

    Tocotrienol

    go.drugbank.com/drugs/DB12647
    Investigational

    Tocotrienol has been investigated for the treatment of Cholesterol Lowering.

    Mixtures: NHF Tocotrienol E Plus Vitamin D3 SoftgelCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Montmorillonite

    go.drugbank.com/drugs/DB13654
    Investigational

    Mixtures: Dr. SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampooCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success.

    Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker
  7. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822]. … Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac.

  8. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    Metrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … A total of 10, 000 injections were administered to 2,028 patients undergoing angiocardiographic procedures over a three-year period.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. … Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.

  10. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia due … It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515].